Paclitaxel albumin injection, also known by its brand name Abraxane, is a form of the chemotherapy drug paclitaxel that is bound to human albumin, a type of protein. This formulation allows the paclitaxel to be administered to patients without the need for solvents, which can cause allergic reactions in some patients.

Paclitaxel albumin injection is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer. It works by inhibiting the growth of cancer cells.

The patent for paclitaxel albumin injection, held by the pharmaceutical company Celgene, expired in December 2019 in the United States. This means that generic versions of the drug may now be produced and sold by other manufacturers.

It is important to note that, while generic versions of drugs typically become less expensive after the patent expires, they must still undergo rigorous testing and approval by regulatory agencies such as the US Food and Drug Administration (FDA) to ensure that they are safe and effective.

In summary, paclitaxel albumin injection is a form of the chemotherapy drug paclitaxel that is bound to human albumin, and it is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer. The patent for paclitaxel albumin injection expired in December 2019, which may lead to the availability of generic versions of the drug.

Sources:

* [DrugPatentWatch.com: Paclitaxel Albumin Injection](https://www.drugpatentwatch.com/drugs/paclitaxel-albumin-injection)
* [FDA: Paclitaxel Albumin-Stabilized Nanoparticle Formulation](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125337s013lbl.pdf)
* [National Cancer Institute: Paclitaxel Albumin-Stabilized Nanoparticle Formulation](https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel-albumin-stabilized-nanoparticle-formulation)